Philip McCarthy's guest appearances

Philip McCarthy

Oncology Data Advisor

CureTalks

HealthTree Podcast for Multiple Myeloma

WBEN Extras

EHA 2016

Johns Hopkins

Stephen Russell

Adam Cohen

David Siegel

Mike Thompson

Atopic Dermatitis

Beth Israel

Damian Green

Sarah Cannon

Keith Stewart

Mark Newman

Paul Richardson

Jorge Sierra

Stephen Harding

Steven Horwitz

OwlTail

Philip McCarthy, MD is the director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York. He has been in oncology practice for more than 20 years. His research interests include patient outcomes after blood and marrow transplantation, blood and marrow stem cell isolation, and preclinical models of bone marrow transplantation. He spoke with Oncology Data Advisor about when to consider bone marrow transplantation (BMT), barriers to transplant referrals, the improved safety of unrelated donor transplants, and the use of transplants in elderly patients.Discussion Notes: On the types of transplants and when to consider this procedure [1:10] On the types of lymphoma that may benefit most from BMT [8:01] On the underutilization of BMT and why eligible patients may not receive transplant referrals [10:40] On how oncologists can address barriers to transplant referral [14:55] On the improved outcomes of unrelated donor transplants [16:48] On the use of BMT in elderly patients [21:48]

Philip McCarthy, MD is the director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute in Buffalo, New York. He has been in oncology practice for more than 20 years. His research interests include patient outcomes after blood and marrow transplantation, blood and marrow stem cell isolation, and preclinical models of bone marrow transplantation. He spoke with Oncology Data Advisor about when to consider bone marrow transplantation (BMT), barriers to transplant referrals, the improved safety of unrelated donor transplants, and the use of transplants in elderly patients. Discussion Notes: On the types of transplants and when to consider this procedure [1:10] On the types of lymphoma that may benefit most from BMT [8:01] On the underutilization of BMT and why eligible patients may not receive transplant referrals [10:40] On how oncologists can address barriers to transplant referral [14:55] On the improved outcomes of unrelated donor transplants [16:48] On the use of BMT in elderly patients [21:48]

Bone Marrow Transplant in Cancer Care With Philip McCarthy, MD

Stem cell transplants will continue to be a staple of multiple myeloma therapy because they are highly effective. But can we add something before or after transplant to make them even more powerful? With new maintenance therapies showing greater overall survival and with new drugs and immunotherapies in the mix, what can we add on the front or back end to make transplant even better? Hear from Dr. Philip McCarthy from the Roswell Park Cancer Institute, a stem cell transplant expert, about the use of maintenance treatments and up-front options that can give patients more durable outcomes.

Myeloma Crowd Radio: Dr. Philip McCarthy, Roswell Park Cancer Institute

Dr McCarthy talks to ecancertv at EHA 2016 about a meta-analysis into the efficacy of lenalidomide (LEN) maintenance to treat multiple myeloma (MM) following high-dose melphalan and autologous stem cell transplant (HDM ASCT).LEN has proven efficacious in reducing disease progression, but these studies were not powered for overall survival (OS).In analysing data from 1,200 patients, gathered over three previous trials (IFM 2005-02, CALGB 100104 [Alliance], GIMEMA RV-209) that match the criteria (had patient-level data, had a control arm, and achieved database lock for primary efficacy analysis of patients with newly diagnosed MM receiving LEN post ASCT), Dr McCarthy reports that LEN maintenance significantly prolongs OS compared to control.He encourages LEN maintenance as the standard of care HDM ASCT, and introduces further studies into LEN as a single agent or as part of a therapeutic combination.

Dr McCarthy talks to ecancertv at EHA 2016 about a meta-analysis into the efficacy of lenalidomide (LEN) maintenance to treat multiple myeloma (MM) following high-dose melphalan and autologous stem cell transplant (HDM ASCT). LEN has proven efficacious in reducing disease progression, but these studies were not powered for overall survival (OS). In analysing data from 1,200 patients, gathered over three previous trials (IFM 2005-02, CALGB 100104 [Alliance], GIMEMA RV-209) that match the criteria (had patient-level data, had a control arm, and achieved database lock for primary efficacy analysis of patients with newly diagnosed MM receiving LEN post ASCT), Dr McCarthy reports that LEN maintenance significantly prolongs OS compared to control. He encourages LEN maintenance as the standard of care HDM ASCT, and introduces further studies into LEN as a single agent or as part of a therapeutic combination.

Meta-analysis of overall survival in multiple myeloma treated with lenalidomide - Dr Philip McCarthy